The neuromuacular blocking effects of the repeated bolus injection and continuous injection of vecuronium have been compared in 20 patients by means of evoked twitch tension. Group I received a loading dose (0.08 mg/kg) of vecuronium and followed by maintenance doae (0.02 mg/kg) when twitch tension had recovered to 25% of control. Group II received a loading doses (0. 08mg/kg) of vecuronium plus a continuous infusion delivering 0.06 mg/kg/hr. Anesthesia was maintained with nitrous oxide, oxygen and 1.5% enflurane. The neuromuscular blocking effect were reversed by the neostigmine 1.0 mg and robinul 0.2 mg when twitch tension had recovered 25% control in both groups near the end of operation. With repeated injection of vecuronium (group I), the duration of blockade of 25% recovery was 21.6+/-4.2 minutes and the recovery times from 25% to 75% was 6.8+/-1.9 minutes The continuous infusion of vecuronium (group II) produced consistent neuromuscular blockade at the average level of 90% twitch depression. The times from the end of infusion to 25% and fr,om 25% to 75% are averaged 16.0+/-2.5 and 4.2+/-0.7 minutes respectively. The reeovery index was more rapid in infusion group than maintenance group (P<0.05).
Anesthesia ; Depression ; Enflurane ; Humans ; Neostigmine ; Neuromuscular Blockade ; Nitrous Oxide ; Oxygen ; Vecuronium Bromide*

Juvenile xanthogranuloma is a congenital or perinatal tumor, 1 to 2 cm in diameter, usually located on the head. The extracutaneous lesions can occur on the eye, the lung, the epicardium, the oral cavity or the testicles. Subcutaneous form of juvenile xanthogranuloma has been reported very rarely in the literature. We report a unique case of a subcutaneous juvenile xanthogranuloma that showed 4 × 4 cm sized plaque and located on the extremity of 9-year-old girl.
Child ; Extremities ; Female ; Head ; Humans ; Lung ; Mouth ; Pericardium ; Testis ; Xanthogranuloma, Juvenile*

No abstract available.

Regenerative medicine (RM) aims to replace or regenerate human cells, tissues, or organs to restore or establish the normal function. RM comprises cells, biomaterials for scaffolds, and growth factors. The cells play an important role in regenerative medicine. Biomaterials can form tissue and transmit biological activity signals and promote cell adhesion. The biological growth factor is a signal transmitter necessary to regenerate tissues and organs. Bioprinting as a powerful tool for building tissue and organ structures in the field of tissue engineering has attracted enormous attention as a fabrication methodology for producing 3-dimensional structures. Bioprinting technology will be needed to treat musculoskeletal diseases. This paper will provide information that can be used as a regenerative medicine treatment for musculoskeletal diseases. It will enable the regeneration of the musculoskeletal system consisting of bones, joints, muscles, and nerves.

Superficial bladder tumors are usually treated by TUR. However, recurrence of the tumor after complete resection occurs in about 50-70%, of the patients with a significant percentage of these recurrences showing a higher degree of malignancy. In 10% of the cases, the tumor progresses to invasive carcinoma. Most of these recurrent tumors will occur within 6-12 months. The multifocal nature of these tumors and the frequent recurrences after TUR indicate a need for adjuvant chemotherapy to reduce or delay the incidence of recurrence tumors. We studied to evaluate prophylactic effects of topical chemotherapy in 116 cases with superficial bladder tumors admitted to the Department of Urology, Keimyung University School of Medicine during the period from Jenuary, 1971 through July, 1985. All patients were followed up for more than 6 months. Study group consists of 83 cases (Thio-tepa: 39, Adriamycin; 44) treated with topical chemotherapy following TUR during the period from January, 1978 through July, 1985. Control group consists of 33 cases treated by TUR only during the period from January 1971 through December, 1977. Following results were obtained: 1. No. of patients with recurrence; In study group, 36Pr In control group. 67% 2. Average interval of recurrence: In study group, 38 months. In control group, 30 months 3. Recurrence rate; In study group, 2.58 In control group, 3.16 4. Complication: local side effects; In TUR + Thio-tepa, 20.5% In TUR + Adriamycin, 15.9%.
Chemotherapy, Adjuvant ; Doxorubicin ; Drug Therapy* ; Humans ; Incidence ; Recurrence ; Thiotepa ; Urinary Bladder Neoplasms* ; Urinary Bladder* ; Urology

No abstract available.
Female ; Pregnancy ; Pregnancy, Ectopic* ; Salpingectomy*

No abstract available.
Arteries* ; Cardiomyopathy, Hypertrophic* ; Humans ; Infant* ; Mothers*

No abstract available.
Adult* ; Dental Pulp Cavity* ; Humans ; Incisor*

Review of renal cell carcinoma was made on 28 cases admitted to Dept. of Urology during the period of 11 years from September 1, 1972 through September 30, 1983. 1. There were 17 males and females (ratio of 1.5:1) ranged in age from 19 to 69 years with peak incidence in the 6th decade. 2. The most common symptom and sign was hematuria in 75% but the classic triad of this tumor was present in 29%. 3. The abnormal laboratory findings were elevated ESR in 75%, anemia in 64%, and reversed A/G ratio without hepatic metastasis in 14%. 4. On the urogram renal mass was found in 50%, calyceal destruction in 48%, and nonvisualization of kidney in 39%. 5. The renal angiogram of 10 cases demonstrate hypervascularity in 7 cases, hypovascularity in 1 case, and tumor staining in 7 cases. 6. Staging of the tumor revealed stage in 13 cases, stage III in 5 cases, and stage IV in 7 cases. 7. The histological type revealed clear cell in 20 cases, granular cell in 1 case, and mixed cell in 7 cases. 8. Treatments were simple nephrectomy in 16 cases, simple nephrectomy with adjuvant therapy in 3 cases, and radical nephrectomy with adjuvant therapy in 5 cases.
Anemia ; Carcinoma, Renal Cell* ; Female ; Hematuria ; Humans ; Incidence ; Kidney ; Male ; Neoplasm Metastasis ; Nephrectomy ; Urology

No abstract available.
Female ; Humans ; Osteoporosis* ; Uterine Prolapse*